DK2435410T3 - LXR-modulatorer - Google Patents

LXR-modulatorer Download PDF

Info

Publication number: DK2435410T3
Authority: DK; Denmark
Prior art keywords: lxr modulators; lxr; modulators
Prior art date: 2009-05-28

Application number

DK10721902.4T

Other languages

English (en)

Inventor

Brett B Busch

Ellen K Kick

Haiying Zhang

Venkataiah Bollu

Richard Martin

Raju Mohan

William C Stevens Jr

Original Assignee

Exelixis Patent Co Llc

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-28

Filing date

2010-05-26

Publication date

2017-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43223342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2435410(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-05-26 Application filed by Exelixis Patent Co Llc, Bristol Myers Squibb Co filed Critical Exelixis Patent Co Llc

2017-04-10 Application granted granted Critical

2017-04-10 Publication of DK2435410T3 publication Critical patent/DK2435410T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK10721902.4T 2009-05-28 2010-05-26 LXR-modulatorer DK2435410T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18173609P	2009-05-28	2009-05-28
PCT/US2010/036211 WO2010138598A2 (en)	2009-05-28	2010-05-26	Lxr modulators

Publications (1)

Publication Number	Publication Date
DK2435410T3 true DK2435410T3 (da)	2017-04-10

Family

ID=43223342

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10721902.4T DK2435410T3 (da)	2009-05-28	2010-05-26	LXR-modulatorer

Country Status (31)

Country	Link
US (4)	US8618154B2 (da)
EP (1)	EP2435410B1 (da)
JP (1)	JP5625050B2 (da)
KR (1)	KR101676704B1 (da)
CN (1)	CN102648184B (da)
AR (1)	AR078049A1 (da)
AU (1)	AU2010254082B2 (da)
BR (1)	BRPI1013259B8 (da)
CA (1)	CA2761934C (da)
CL (1)	CL2011002972A1 (da)
CO (1)	CO6470826A2 (da)
CY (1)	CY1119407T1 (da)
DK (1)	DK2435410T3 (da)
EA (1)	EA019960B1 (da)
ES (1)	ES2620451T3 (da)
HR (1)	HRP20170194T1 (da)
IL (1)	IL216176A (da)
LT (1)	LT2435410T (da)
MX (1)	MX2011012559A (da)
MY (1)	MY153958A (da)
NZ (1)	NZ596330A (da)
PE (1)	PE20120797A1 (da)
PL (1)	PL2435410T3 (da)
PT (1)	PT2435410T (da)
SG (1)	SG176247A1 (da)
SI (1)	SI2435410T1 (da)
SM (1)	SMT201700253T1 (da)
TN (1)	TN2011000585A1 (da)
TW (1)	TWI488844B (da)
WO (1)	WO2010138598A2 (da)
ZA (1)	ZA201108181B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101676704B1 (ko) *	2009-05-28	2016-11-16	엑셀리시스 페이턴트 컴퍼니 엘엘씨	Ｌｘｒ 조절자
AR088728A1 (es) *	2011-03-25	2014-07-02	Bristol Myers Squibb Co	Moduladores de lxr como prodroga de imidazol
SG10201607345YA (en)	2012-03-02	2016-11-29	Ralexar Therapeutics Inc	Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
AU2013302861A1 (en)	2012-08-13	2015-03-05	The Rockefeller University	Treatment and diagnosis of melanoma
JP6456909B2 (ja)	2013-03-15	2019-01-23	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｌｘｒ調節因子
CN105209039B (zh) *	2013-03-15	2018-06-22	百时美施贵宝公司	Lxr调节剂
RS60479B1 (sr)	2013-09-04	2020-08-31	Ellora Therapeutics Inc	Modulatori receptora x jetre (lxr)
JP2016532713A (ja)	2013-09-04	2016-10-20	アレクサーセラピューティクス，インク．	肝臓ｘ受容体（ｌｘｒ）調節因子
WO2015106164A1 (en)	2014-01-10	2015-07-16	Rgenix, Inc.	Lxr agonists and uses thereof
KR101815734B1 (ko)	2015-05-29	2018-01-05	가톨릭대학교 산학협력단	ｍｉＲ－７, ｍｉＲ－１８ａ 또는 ｍｉＲ－１８ｂ를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물
EP3402477A4 (en)	2016-01-11	2019-08-21	The Rockefeller University	METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS
CA3078981A1 (en)	2017-11-21	2019-05-31	Rgenix, Inc.	Polymorphs and uses thereof
EP3999055A1 (en)	2019-07-15	2022-05-25	Novartis AG	Methods for treating meibomian gland dysfunction with liver x receptor agonists
CN110305141B (zh) *	2019-07-18	2022-01-11	深圳市三启药物开发有限公司	一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用
TWI888447B (zh)	2019-12-13	2025-07-01	美商因思博納公司	金屬鹽及其用途
CN115656401B (zh) *	2022-11-09	2025-03-28	武汉海特生物创新医药研究有限公司	一种咪唑-4-甲酸乙酯纯度的hplc检测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
US4444784A (en)	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
DK149080C (da)	1980-06-06	1986-07-28	Sankyo Co	Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
HU204253B (en)	1982-11-22	1991-12-30	Sandoz Ag	Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en)	1990-12-14	1993-01-05	Bayer Aktiengesellschaft	Substituted pyridyl-dihydroxy-heptenoic acid and its salts
CA2115452A1 (en)	1991-09-17	1993-04-01	Ronald M. Evans	Receptor of the thyroid/steroid hormone receptor superfamily
CN1248916A (zh)	1997-01-24	2000-03-29	加利福尼亚大学董事会	FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途
EP1115853A2 (en)	1998-09-23	2001-07-18	Ludmila Solomin	Analysis of ligand activated nuclear receptors in vivo
JP2002532729A (ja)	1998-12-23	2002-10-02	グラクソグループリミテッド	核内受容体のリガンドのアッセイ
EP1165135B1 (en)	1999-03-26	2004-09-01	City of Hope	Methods of screening for compounds modulating fxr receptors
CN100513570C (zh)	1999-06-18	2009-07-15	Cv治疗公司	结合框运输蛋白abc1的调节作用
WO2001082917A2 (en)	2000-05-03	2001-11-08	Tularik Inc.	Treatment of hypertriglyceridemia and other conditions using lxr modulators
US6924311B2 (en)	2001-10-17	2005-08-02	X-Ceptor Therapeutics, Inc.	Methods for affecting various diseases utilizing LXR compounds
US7482366B2 (en) *	2001-12-21	2009-01-27	X-Ceptor Therapeutics, Inc.	Modulators of LXR
WO2004011446A1 (en) *	2002-07-26	2004-02-05	Bayer Pharmaceuticals Corporation	Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
US7109227B2 (en) *	2002-08-26	2006-09-19	National Health Research Institutes	Imidazolamino compounds
MXPA05012679A (es) *	2003-05-27	2006-02-08	Sod Conseils Rech Applic	Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
CA2545942C (en) *	2003-11-14	2012-07-10	Lorus Therapeutics Inc.	Aryl imidazoles and their use as anti-cancer agents
AU2005211809B2 (en) *	2004-02-11	2009-02-12	Irm Llc	Compounds and compositions as LXR modulators
BRPI0612287A8 (pt) *	2005-06-27	2019-01-22	Exelixis Inc	composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
SG162803A1 (en) *	2005-06-27	2010-07-29	Exelixis Inc	Imidazole based lxr modulators
KR20090094125A (ko) *	2006-12-08	2009-09-03	엑셀리시스, 인코포레이티드	Ｌｘｒ 및 ｆｘｒ 조절자
KR101676704B1 (ko) *	2009-05-28	2016-11-16	엑셀리시스 페이턴트 컴퍼니 엘엘씨	Ｌｘｒ 조절자

2010
- 2010-05-26 KR KR1020117031397A patent/KR101676704B1/ko not_active Expired - Fee Related
- 2010-05-26 JP JP2012513215A patent/JP5625050B2/ja not_active Expired - Fee Related
- 2010-05-26 AU AU2010254082A patent/AU2010254082B2/en not_active Ceased
- 2010-05-26 BR BRPI1013259A patent/BRPI1013259B8/pt not_active IP Right Cessation
- 2010-05-26 CN CN201080033601.2A patent/CN102648184B/zh not_active Expired - Fee Related
- 2010-05-26 EA EA201171488A patent/EA019960B1/ru not_active IP Right Cessation
- 2010-05-26 EP EP10721902.4A patent/EP2435410B1/en active Active
- 2010-05-26 DK DK10721902.4T patent/DK2435410T3/da active
- 2010-05-26 PT PT107219024T patent/PT2435410T/pt unknown
- 2010-05-26 PE PE2011002005A patent/PE20120797A1/es active IP Right Grant
- 2010-05-26 WO PCT/US2010/036211 patent/WO2010138598A2/en not_active Ceased
- 2010-05-26 LT LTEP10721902.4T patent/LT2435410T/lt unknown
- 2010-05-26 SI SI201031427A patent/SI2435410T1/sl unknown
- 2010-05-26 NZ NZ596330A patent/NZ596330A/xx unknown
- 2010-05-26 ES ES10721902.4T patent/ES2620451T3/es active Active
- 2010-05-26 CA CA2761934A patent/CA2761934C/en active Active
- 2010-05-26 MX MX2011012559A patent/MX2011012559A/es active IP Right Grant
- 2010-05-26 HR HRP20170194TT patent/HRP20170194T1/hr unknown
- 2010-05-26 SM SM20170253T patent/SMT201700253T1/it unknown
- 2010-05-26 US US13/319,937 patent/US8618154B2/en not_active Expired - Fee Related
- 2010-05-26 SG SG2011087459A patent/SG176247A1/en unknown
- 2010-05-26 MY MYPI2011006278A patent/MY153958A/en unknown
- 2010-05-26 PL PL10721902T patent/PL2435410T3/pl unknown
- 2010-05-28 AR ARP100101870A patent/AR078049A1/es not_active Application Discontinuation
- 2010-05-28 TW TW099117252A patent/TWI488844B/zh not_active IP Right Cessation
2011
- 2011-11-07 IL IL216176A patent/IL216176A/en active IP Right Grant
- 2011-11-08 ZA ZA2011/08181A patent/ZA201108181B/en unknown
- 2011-11-16 TN TNP2011000585A patent/TN2011000585A1/en unknown
- 2011-11-24 CL CL2011002972A patent/CL2011002972A1/es unknown
- 2011-11-25 CO CO11161736A patent/CO6470826A2/es active IP Right Grant
2013
- 2013-11-21 US US14/085,926 patent/US20140163081A1/en not_active Abandoned
2015
- 2015-05-04 US US14/703,247 patent/US20150299136A1/en not_active Abandoned
2016
- 2016-06-07 US US15/175,425 patent/US20160280661A1/en not_active Abandoned
2017
- 2017-04-05 CY CY20171100403T patent/CY1119407T1/el unknown

Also Published As

Publication number	Publication date
EA019960B1 (ru)	2014-07-30
JP5625050B2 (ja)	2014-11-12
CO6470826A2 (es)	2012-06-29
TWI488844B (zh)	2015-06-21
AU2010254082B2 (en)	2015-01-29
CY1119407T1 (el)	2018-03-07
BRPI1013259B8 (pt)	2021-05-25
US8618154B2 (en)	2013-12-31
HRP20170194T1 (hr)	2017-05-19
ZA201108181B (en)	2013-01-30
JP2012528180A (ja)	2012-11-12
TW201109308A (en)	2011-03-16
BRPI1013259B1 (pt)	2021-04-13
CN102648184A (zh)	2012-08-22
CA2761934C (en)	2018-01-09
MX2011012559A (es)	2012-06-08
KR20120047868A (ko)	2012-05-14
IL216176A (en)	2015-10-29
EP2435410B1 (en)	2017-01-18
AU2010254082A1 (en)	2011-12-08
NZ596330A (en)	2013-07-26
PE20120797A1 (es)	2012-07-08
SG176247A1 (en)	2012-01-30
EP2435410A2 (en)	2012-04-04
CL2011002972A1 (es)	2012-08-17
KR101676704B1 (ko)	2016-11-16
TN2011000585A1 (en)	2013-05-24
EA201171488A1 (ru)	2012-07-30
PL2435410T3 (pl)	2017-07-31
SMT201700253T1 (it)	2017-07-18
US20160280661A1 (en)	2016-09-29
MY153958A (en)	2015-04-30
US20120071534A1 (en)	2012-03-22
IL216176A0 (en)	2012-01-31
ES2620451T3 (es)	2017-06-28
WO2010138598A2 (en)	2010-12-02
LT2435410T (lt)	2017-04-10
SI2435410T1 (sl)	2017-06-30
CN102648184B (zh)	2015-09-30
BRPI1013259A2 (pt)	2016-04-05
PT2435410T (pt)	2017-05-03
US20150299136A1 (en)	2015-10-22
US20140163081A1 (en)	2014-06-12
AR078049A1 (es)	2011-10-12
WO2010138598A3 (en)	2011-07-28
CA2761934A1 (en)	2010-12-02

Publication	Publication Date	Title
FIC20220037I1 (fi)	2022-08-31	Tebentafuspi
DK2435410T3 (da)	2017-04-10	LXR-modulatorer
PT2414891T (pt)	2017-02-17	Dispositivos electrocrómicos
DE112010002949A5 (de)	2012-09-06	Kupplungstastpunkte
EP2491340A4 (en)	2014-12-24	TELEMETRY PHOTOGRAPHIC APPARATUS
EP2509489A4 (en)	2015-04-01	SPRINKLER FOR EARLY HEEL REMOVAL
DK2512451T3 (da)	2016-06-06	Modulator
EP2446176A4 (en)	2016-12-14	CYLINDER SEAL
DE112009005462T8 (de)	2013-03-28	Lenkungsssteuervorrichtung
HUE038760T2 (hu)	2018-11-28	Hulladékhõ-visszanyerõrendszer
IT1393701B1 (it)	2012-05-08	Rampone
FI20095754A0 (fi)	2009-07-03	Tuloilmalaite
FI20095698A0 (fi)	2009-06-18	Kaavinterämateriaali
FR2949748B1 (fr)	2011-12-09	Bouee-balise
DE102009034429A8 (de)	2012-01-05	Flachantenne
FI20090173A0 (fi)	2009-04-29	Pystypuun karsintalaite
EE00869U1 (et)	2009-10-15	Korduvkasutusega martappliide
FR2944548B1 (fr)	2015-05-15	Cremone-serrure
FI8438U1 (fi)	2009-09-15	Osastoija
FI8729U1 (fi)	2010-05-25	Jyrsinturvekääntäjä
FI9124U1 (fi)	2011-02-28	Maustesirotin
ES1069841Y (es)	2009-09-07	Arqueta
IT1397146B1 (it)	2013-01-04	Automotobarca
FI20095898A0 (fi)	2009-09-01	Kuivajääpuhallin
PL389606A1 (pl)	2011-05-23	2-Tienyloanalog nerolidolu